Certara, Inc. (NASDAQ:CERT) Given Consensus Recommendation of “Moderate Buy” by Analysts

Certara, Inc. (NASDAQ:CERT) has been given a consensus recommendation of “Moderate Buy” by the fifteen research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $13.8182.

Several research analysts have commented on the company. Redburn Partners set a $10.00 price objective on Certara in a report on Friday, November 21st. Rothschild Redb raised Certara to a “strong-buy” rating in a research report on Friday, November 21st. Zacks Research upgraded Certara from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. Barclays lowered their price objective on shares of Certara from $16.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday, November 7th. Finally, UBS Group cut their target price on shares of Certara from $17.50 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th.

Insider Buying and Selling

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total transaction of $559,366.08. Following the completion of the sale, the insider owned 73,979 shares in the company, valued at $807,850.68. This represents a 40.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 2.33% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. AdvisorNet Financial Inc purchased a new stake in shares of Certara during the 2nd quarter worth $25,000. First Horizon Corp purchased a new position in Certara in the third quarter valued at about $30,000. Caitong International Asset Management Co. Ltd bought a new position in Certara in the first quarter worth about $31,000. Versant Capital Management Inc raised its holdings in Certara by 66.7% in the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock worth $35,000 after purchasing an additional 1,153 shares in the last quarter. Finally, AlphaQuest LLC purchased a new stake in shares of Certara during the first quarter valued at about $39,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Price Performance

Certara stock opened at $9.16 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of 130.79 and a beta of 1.44. The firm has a 50-day moving average of $11.06 and a two-hundred day moving average of $11.04. Certara has a 1 year low of $8.02 and a 1 year high of $15.69.

Certara (NASDAQ:CERT) last issued its earnings results on Thursday, November 6th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. The business had revenue of $104.62 million for the quarter, compared to analyst estimates of $104.53 million. Certara had a net margin of 2.62% and a return on equity of 5.18%. During the same period last year, the company posted $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. On average, research analysts forecast that Certara will post 0.28 earnings per share for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.